Lower dolutegravir plasma concentrations in HIV-positive patients receiving valproic acid

J Antimicrob Chemother. 2018 Mar 1;73(3):826-827. doi: 10.1093/jac/dkx461.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Anticonvulsants / administration & dosage
  • Anticonvulsants / therapeutic use*
  • Drug Interactions
  • Female
  • HIV Infections / complications
  • HIV Infections / drug therapy*
  • HIV Integrase Inhibitors / blood*
  • HIV Integrase Inhibitors / therapeutic use
  • Heterocyclic Compounds, 3-Ring / blood*
  • Heterocyclic Compounds, 3-Ring / therapeutic use
  • Humans
  • Oxazines
  • Piperazines
  • Pyridones
  • Registries
  • Valproic Acid / administration & dosage
  • Valproic Acid / therapeutic use*

Substances

  • Anticonvulsants
  • HIV Integrase Inhibitors
  • Heterocyclic Compounds, 3-Ring
  • Oxazines
  • Piperazines
  • Pyridones
  • Valproic Acid
  • dolutegravir